Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 35Recruiting 7Active not recruiting 3Unknown 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2Gastrointestinal 2

Conditions

Breast Neoplasms 846Carcinoma, Non-Small-Cell Lung 553Neoplasms 516Prostatic Neoplasms 503Lung Neoplasms 312Colorectal Neoplasms 304Multiple Myeloma 295Neoplasm Metastasis 255Melanoma 244Ovarian Neoplasms 215Leukemia, Myeloid, Acute 212Pancreatic Neoplasms 203Squamous Cell Carcinoma of Head and Neck 171Carcinoma, Renal Cell 166Stomach Neoplasms 160Recurrence 159Lymphoma 159Carcinoma, Hepatocellular 159Glioblastoma 151Brain Neoplasms 151Lymphoma, Non-Hodgkin 143Uterine Cervical Neoplasms 142Head and Neck Neoplasms 141Urinary Bladder Neoplasms 137Leukemia, Lymphocytic, Chronic, B-Cell 137Triple Negative Breast Neoplasms 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Hematologic Neoplasms 117Colonic Neoplasms 117Lymphoma, Follicular 114

Interventions

etoposide phosphate 1Paclitaxel 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Endodermal Sinus Tumor × Clear all
NCT05103631 2026-03-06

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

Baylor College of Medicine

Phase 1 Active not recruiting
12 enrolled
GastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Liposarcoma, Liver Neoplasms, Wilms Tumor, Rhabdomyosarcoma, Endodermal Sinus Tumor, Rhabdoid Tumor

NCT04377932 2026-01-21

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Baylor College of Medicine

Phase 1 Active not recruiting
14 enrolled 12 charts
GastrointestinalGenitourinarySarcoma

Liposarcoma, Liver Neoplasms, Wilms Tumor, Rhabdomyosarcoma, Endodermal Sinus Tumor, Rhabdoid Tumor

NCT02375204 2025-01-13

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Alliance for Clinical Trials in Oncology

Phase 3 Active not recruiting
420 enrolled

Nonseminomatous germ cell tumor, Choriocarcinoma, Neoplasms, Germ Cell and Embryonal, Teratoma, Germinoma, Seminoma, Endodermal Sinus Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡